https://www.selleckchem.com/products/bx-795.html
Background Rituximab has become one of the first-line therapies for the treatment of moderate and high-risk primary membranous nephropathy (pMN). We retrospectively reviewed 95 patients with pMN who received rituximab therapy and focused on the therapeutic effects and safety of this therapy in a Chinese cohort. Methods Ninety-five consecutive patients with pMN diagnosed by kidney biopsy received rituximab and were followed up for 6 months. Four weekly doses of rituximab (375 mg/m2) was adopted as the initial administration. Repeated
Curtir
Comentario
Compartilhar
